OP13.05: Assessment of the angiogenic ratio versus glycosylated fibronectin in predicting adverse maternal outcome in women with suspected pre‐eclampsia

Documenti analoghi

• EP17.54: Assessment of the angiogenic ratio versus glycosylated fibronectin in predicting adverse neonatal outcome in women with suspected pre‐eclampsia
  di: Y. Wah, et al.
  Pubblicazione: (2024)
• EP17.06: Inter‐manufacturer assessment of the diagnostic performance of angiogenic ratio versus glycosylated fibronectin in women with suspected pre‐eclampsia
  di: Y. Wah, et al.
  Pubblicazione: (2024)
• Intermanufacturer assessment of diagnostic performance of angiogenic ratio vs glycosylated fibronectin in women with suspected pre‐eclampsia
  di: I. Y. M. Wah, et al.
  Pubblicazione: (2024)
• Screening for pre‐eclampsia by maternal serum glycosylated fibronectin and angiogenic markers at 36 weeks' gestation
  di: N. Sokratous, et al.
  Pubblicazione: (2024)
• OC01.02: *Effect of aspirin on placental biomarkers profile in high‐risk women for pre‐eclampsia
  di: L. Nguyen Hoang, et al.
  Pubblicazione: (2024)